NCT03562052 Lung Cancer Screening in a Population Exposed to Occupational Lung Carcinogens
| NCT ID | NCT03562052 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Intercommunal Creteil |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2021-07-22 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2021-07-22 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The good clinical practice guidelines for the surveillance of workers after occupational exposure to lung carcinogens were approved by the Haute Autorité de la Santé (French National Authority for Health) and the Institut National du Cancer (French National Cancer Institute) in December 2015 and one recommendation of these guidelines concerns the setting-up of a trial of low-dose chest computed tomography (CT) lung cancer screening in subjects occupationally exposed to lung carcinogens at high-risk of lung cancer (Expert consensus). In LUCSO study, the investigators propose to conduct, under strictly defined conditions, a feasibility study of lung cancer screening in a population defined as being at high risk of lung cancer according to these good clinical practice guidelines. This population consists of smokers, aged from 55 to 74 years, currently or previously exposed to International Agency for Research on Cancer lung group 1 lung carcinogens. The primary objective of this study is to evaluate the complex organization of lung cancer screening in the target population. This evaluation will focus on the following indicators: * Screening activity indicator: screening coverage rate over two years * Test quality indicator: validity of self-administered questionnaires to target the high-risk population * Examination quality indicator: lung cancer detection rate, lung cancer detection rates by stage, validity of low-dose chest CT scan * Follow-up indicator: smoking cessation rate, mortality rate This trial will be conducted in 8 French departments, by six reference centers specialized in occupational health (SRC). In view of the exploratory nature of this trial, it is proposed to initially test the feasibility and acceptability of lung cancer screening sequentially over the first two years (Phase 1: 2021-2023, 24 months) in only two SRC (Val-de-Marne and Gironde). The trial will be conducted in several steps: 1. Identification of subjects currently or previously occupationally exposed to lung carcinogens by a screening invitation letter sent by Departmental Cancer Screening Centers to subjects aged from 55 to 74 years. 2. Evaluation of occupational exposure to lung carcinogens 3. Evaluation of the lung cancer risk level and verification of eligibility 4. Screening procedure: Chest CT scans will be performed by centers specialized in chest imaging 5. Lung cancer follow-up when an abnormality suggestive of lung cancer is demonstrated.
Eligibility Criteria
Inclusion Criteria: Subjects at high risk of lung cancer: current smokers smoking 30 pack-years or more or ex-smokers smoking 30 pack-years or more and who have quit smoking for less than 15 years and currently or previously occupationally exposed to lung carcinogens. With an algorithm for determination of minimal duration of exposure to occupational carcinogens (according to the type and duration of occupational lung carcinogens) Exclusion Criteria: * Presence of clinical signs of lung cancer * Subjects with a history of lung cancer * Presence of serious short-term life-threatening comorbidities * Absence of occupational exposure to lung carcinogens according to the predefined criteria * Subjects already included in another prospective cohort study * Subjects already assessed by chest CT scan during the previous year * No tobacco exposure or insufficient tobacco exposure or smoking cessation for more than 15 years.
Contact & Investigator
Jean-Claude Pairon, Pr
PRINCIPAL INVESTIGATOR
Centre Hospitalier Interconnmunal de Créteil
Frequently Asked Questions
Who can join the NCT03562052 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 74 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03562052 currently recruiting?
Yes, NCT03562052 is actively recruiting participants. Contact the research team at JC.Pairon@chicreteil.fr for enrollment information.
Where is the NCT03562052 trial being conducted?
This trial is being conducted at Bordeaux, France, Bordeaux, France, Brest, France, Caen, France and 4 additional locations.
Who is sponsoring the NCT03562052 clinical trial?
NCT03562052 is sponsored by Centre Hospitalier Intercommunal Creteil. The principal investigator is Jean-Claude Pairon, Pr at Centre Hospitalier Interconnmunal de Créteil. The trial plans to enroll 6,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.